

Dupilumab Improves Symptoms and Quality of Life in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: RELIEVE-AD-PED Study

April Armstrong¹, Amy S. Paller^{2,3}, Zhixiao Wang⁴, Kerry Noonan⁵, Min Yang⁶, Chien-Chia Chuang⁵, Cheryl Xiang⁶, Debra Sierka⁵, Brad Shumel⁴, Jingdong Chao⁴, Dimitri Delevry⁴

¹University of California Los Angeles, Los Angeles, CA, USA; ²Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ³Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA; ⁴Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ⁵Sanofi, Cambridge, MA, USA; ⁶Analysis Group, Boston, MA, USA

Conclusion

Dupilumab led to disease control and reduced itch symptoms observed as early as Week 2, significant QoL improvements by Month 1, with results sustained through Month 6 in a real-world study of pediatric patients with moderate-to-severe AD

AD



Full poster download
Copies of the presentation obtained through the QR code are for personal reference only

Objective

To evaluate dupilumab effectiveness on AD symptoms and patient QoL based on interim data from a real-world study in pediatric patients with moderate-to-severe AD

Background

- Dupilumab significantly improved symptoms and QoL of patients with moderate-to-severe AD in clinical trials
- RELIEVE-AD-PED is an ongoing, prospective, longitudinal survey study of pediatric patients aged 6 months to 17 years with moderate-to-severe AD who initiated dupilumab, and their caregivers, recruited from DUPIXENT MyWay[®], a patient support program


Methods

- Eligible patients from the USA and their caregivers completed surveys at baseline and at multiple time points after dupilumab initiation
- In this analysis, survey results up to 6 months from patients aged 6 months to 5 years were included and caregivers completed questions on the patient's behalf or read questions aloud and recorded their children's responses when appropriate
- AD severity and disease control were assessed using POEM and ADCT, respectively
- Itch symptoms were assessed using a 0–10 NRS with a 1-week recall period
- QoL and sleep problems were evaluated using the IDQoL and CDLQI questionnaires, and PROMIS sleep problems per analysis group, respectively
- Due to the nature of this study, surveys are completed on a rolling basis and sample size at each time point varies based on ongoing patient recruitment and time of dupilumab initiation


Results

- Caregivers of 238 patients with AD aged 6 months to 5 years who initiated dupilumab treatment completed baseline surveys on the patients' behalf. The mean (SD) patient age was 3.0 (1.4) years and 137 (57.6%) were male children


Proportion of patients with Itch NRS ≥ 4 at baseline experiencing at least a 4-point clinically meaningful improvement in Itch NRS




Proportion of patients achieving controlled disease (ADCT total score <7)




IDQoL and CDLQI severity categories*



POEM severity categories



PROMIS sleep problems



- Post-treatment time points for controlled disease (ADCT total score <7), POEM, PROMIS sleep problems, IDQoL, and CDLQI were significantly improved from baseline ($P < 0.001$)

AD, atopic dermatitis; ADCT, Atopic Dermatitis Control Tool; CDLQI, Children's Dermatology Life Quality Index; IDQoL, Infants' Dermatitis Quality of Life Index; NRS, Numeric Rating Scale; POEM, Patient-Oriented Eczema Measure; PROMIS, Patient-Reported Outcomes Measurement Information System; QoL, quality of life; SD, standard deviation.

Acknowledgments and funding sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Medical writing/editorial assistance was provided by Maria Coimbra-Dores, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the [Good Publication Practice guidelines](#).

Disclosures: Armstrong A: AbbVie, BMS, Dermavant, Dermira, Janssen, LEO Pharma, Lilly, Modernizing Medicine, Ortho Dermatologics, Regeneron Pharmaceuticals Inc., Sanofi, Science 37, UCB – investigator and/or consultant. Paller AS: AbbVie, BioMendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals Inc., UCB – investigator; Abeona, Arcutis, BioCryst, Boehringer Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO Pharma, Lilly, L'Oréal, MoonLake Immunotherapeutics, Pelthos, Quoin, Regeneron Pharmaceuticals Inc., Sanofi – consultant; AbbVie, Abeona, BioCryst, Daiichi Sankyo, Galderma – data safety monitoring board. Wang Z, Shumel B, Chao J, Delevry D: Regeneron Pharmaceuticals Inc. – employees and shareholders. Noonan K, Chuang C-C, Sierka D: Sanofi – employees, may hold stock and/or stock options in the company. Yang M, Xiang C: Analysis Group (a company that received research funds from Sanofi-Regeneron Pharmaceuticals Inc. during the conduct of the study) – employees.